Trials / Terminated
TerminatedNCT02508649
Selepressin Evaluation Programme for Sepsis-Induced Shock - Adaptive Clinical Trial
A Double-blind, Randomised, Placebo-Controlled, Phase 2b/3 Adaptive Clinical Trial Investigating the Efficacy and Safety of Selepressin as Treatment for Patients With Vasopressor-dependent Septic Shock
- Status
- Terminated
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 868 (actual)
- Sponsor
- Ferring Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a double-blind, randomised, placebo-controlled, two-part adaptive clinical trial. The trial is designed to investigate the efficacy and safety of multiple dosing regimens of selepressin and to confirm the efficacy and safety of one dosing regimen in treatment of adult patients with septic shock requiring vasopressor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | selepressin | |
| DRUG | placebo |
Timeline
- Start date
- 2015-07-01
- Primary completion
- 2017-10-03
- Completion
- 2018-02-26
- First posted
- 2015-07-27
- Last updated
- 2021-04-06
- Results posted
- 2021-04-06
Locations
21 sites across 5 countries: United States, Belgium, Denmark, France, Netherlands
Source: ClinicalTrials.gov record NCT02508649. Inclusion in this directory is not an endorsement.